3 Reasons to Sell STE and 1 Stock to Buy Instead
STERIS currently trades at $226.40 per share and has shown little upside over the past six months, posting a small loss of 4.5%.
STERIS currently trades at $226.40 per share and has shown little upside over the past six months, posting a small loss of 4.5%.
Q2 Holdings has been treading water for the past six months, recording a small loss of 4.1% while holding steady at $78.18.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at First Solar (NASDAQ:FSLR) and its peers.
The past six months have been a windfall for The Honest Company’s shareholders. The company’s stock price has jumped 44.3%, hitting $5.34 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
What a brutal six months it’s been for ASGN. The stock has dropped 27.3% and now trades at $67.80, rattling many shareholders. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Krispy Kreme (NASDAQ:DNUT) and the best and worst performers in the traditional fast food industry.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the personal care industry, including e.l.f. Beauty (NYSE:ELF) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Rapid7 (NASDAQ:RPD) and the best and worst performers in the cybersecurity industry.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Udemy (NASDAQ:UDMY) and the rest of the consumer subscription stocks fared in Q4.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.